v3.22.2.2

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Segment Information |
Schedule of segment reporting information, by segment | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the three months ended
​ | ​ | September 30,
​ |  | 2022 |  | 2021
Revenue |  | ​ |  |  | ​ |
XpresSpa | ​ | $ | 3,557 | ​ | $ | 1,416
XpresTest | ​ | ​ | 6,079 | ​ | ​ | 25,351
Treat | ​ | ​ | 425 | ​ | ​ | —
HyperPointe | ​ | ​ | 675 | ​ | ​ | —
Corporate and other | ​ |  | — | ​ |  | —
Total revenue | ​ | $ | 10,736 | ​ | $ | 26,767
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income (loss) | ​ |  |  | ​ |  |
XpresSpa | ​ | $ | (2,508) | ​ | $ | (1,595)
XpresTest | ​ | ​ | (1,692) | ​ | ​ | 12,015
Treat | ​ | ​ | (1,282) | ​ | ​ | (2,305)
HyperPointe | ​ | ​ | (193) | ​ | ​ | —
Corporate and other | ​ |  | (1,979) | ​ |  | (1,058)
Total operating (loss) income | ​ | $ | (7,654) | ​ | $ | 7,057
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation & Amortization | ​ | ​ | ​ | ​ | ​ | ​
XpresSpa | ​ | $ | 364 | ​ | $ | 340
XpresTest | ​ |  | 576 | ​ |  | 509
Treat | ​ | ​ | 520 | ​ | ​ | —
HyperPointe | ​ | ​ | 86 | ​ | ​ | —
Corporate and other | ​ |  | 18 | ​ |  | 3
Total Depreciation & Amortization | ​ | $ | 1,564 | ​ | $ | 852
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the nine months ended
​ | ​ | September 30,
​ |  | 2022 |  | 2021
Revenue |  | ​ |  |  | ​ |
XpresSpa | ​ | $ | 9,490 | ​ | $ | 2,172
XpresTest | ​ | ​ | 35,928 | ​ | ​ | 42,199
Treat | ​ | ​ | 1,110 | ​ | ​ | —
HyperPointe | ​ | ​ | 1,853 | ​ | ​ | —
Corporate and other | ​ |  | — | ​ |  | —
Total revenue | ​ | $ | 48,381 | ​ | $ | 44,371
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Operating loss | ​ |  |  | ​ |  |
XpresSpa | ​ | $ | (8,921) | ​ | $ | (4,828)
XpresTest | ​ | ​ | 2,576 | ​ | ​ | 14,597
Treat | ​ | ​ | (4,038) | ​ | ​ | (4,115)
HyperPointe | ​ | ​ | (745) | ​ | ​ | —
Corporate and other | ​ |  | (6,744) | ​ |  | (3,719)
Total operating (loss) income | ​ | $ | (17,872) | ​ | $ | 1,935
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation & Amortization | ​ | ​ | ​ | ​ | ​ | ​
XpresSpa | ​ | $ | 1,065 | ​ | $ | 931
XpresTest | ​ |  | 1,711 | ​ |  | 1,604
Treat | ​ | ​ | 1,287 | ​ | ​ | —
HyperPointe | ​ | ​ | 243 | ​ | ​ | —
Corporate and other | ​ |  | 23 | ​ |  | 7
Total depreciation & amortization | ​ | $ | 4,329 | ​ | $ | 2,542
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Capital Expenditures | ​ | ​ | ​ | ​ | ​ | ​
XpresSpa | ​ | $ | 1,413 | ​ | $ | 706
XpresTest | ​ |  | 675 | ​ |  | 3,984
Treat | ​ | ​ | 3,329 | ​ | ​ | —
HyperPointe | ​ | ​ | — | ​ | ​ | —
Corporate and other | ​ |  | 55 | ​ |  | 77
Total capital expenditures | ​ | $ | 5,472 | ​ | $ | 4,767
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, | ​ | December 31,
​ | ​ | 2022 | ​ | 2021
Long-lived Assets | ​ | ​ | ​ | ​ | ​ | ​
XpresSpa | ​ | $ | 14,203 | ​ | ​ | 8,419
XpresTest | ​ |  | 112 | ​ | ​ | 2,246
Treat | ​ | ​ | 6,280 | ​ | ​ | 2,700
HyperPointe | ​ |  | 123 | ​ | ​ | —
Corporate and other | ​ |  | 522 | ​ | ​ | 1,132
Total long-lived Assets | ​ | $ | 21,240 | ​ | $ | 14,497
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, | ​ | December 31,
​ | ​ | 2022 |  | 2021
Assets | ​ |  |  | ​ |  |
XpresSpa | ​ | $ | 21,348 | ​ | $ | 12,351
XpresTest | ​ |  | 5,356 | ​ |  | 19,349
Treat | ​ | ​ | 9,822 | ​ | ​ | 5,918
HyperPointe | ​ | ​ | 7,126 | ​ | ​ | —
Corporate and other | ​ |  | 41,324 | ​ |  | 89,648
Total assets | ​ | $ | 84,976 | ​ | $ | 127,266

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration